WP
AVIR icon

Woodline Partners’s Atea Pharmaceuticals AVIR Stock Holding History

Woodline Partners’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-103,358
Closed -$346K – 930
2024
Q3 		$346K Buy
+103,358
New +$375K ﹤0.01% 552
2022
Q1 		– Sell
-208,399
Closed -$1.86M – 724
2021
Q4 		$1.86M Buy
208,399
+23,134
+12% +$361K 0.03% 433
2021
Q3 		$6.5M Sell
185,265
-2,540
-1% -$70.5K 0.11% 220
2021
Q2 		$4.03M Sell
187,805
-27,868
-13% -$837K 0.08% 244
2021
Q1 		$13.3M Sell
215,673
-60,410
-22% -$4.08M 0.3% 92
2020
Q4 		$11.5M Buy
+276,083
New +$8.9M 0.31% 100

Other funds holding AVIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Woodline Partners's AVIR Position: Q4 2024 in Review

Woodline Partners sold out of Atea Pharmaceuticals (AVIR) in Q4 2024, closing a stake of 103,358 shares — an estimated $346K sold.

Woodline Partners first reported a position in AVIR in Q4 2020 and held it in 6 quarters. The position peaked at $13.3M in Q1 2021. 106 funds tracked by Wall St. Rank hold AVIR as of Q4 2024.

  • Woodline Partners reported no remaining Atea Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Woodline Partners sold 103,358 Atea Pharmaceuticals shares in Q4 2024, an estimated $346K.
  • Woodline Partners first reported a position in Atea Pharmaceuticals in Q4 2020 and held it in 6 quarters.
  • Woodline Partners's Atea Pharmaceuticals position peaked at $13.3M in Q1 2021.
  • 106 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q4 2024.

Based on Woodline Partners's 13F filing for Q4 2024, filed 14 Feb 2025.